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Abstract
Chemo-resistance of breast cancer is a major obstacle for successful treatment and is 
mainly represented as a defect in apoptosis. The differential effects of platinum-based 
drugs (PBDs) were assessed on breast cancer cell ultrastructure. Three representative 
cells, including triple-negative breast cancer (TNBC), were treated with different con-
centrations and timings of cisplatin, carboplatin, and oxaliplatin. Changes on cell surface 
and ultrastructure were detected by scanning electron microscope (SEM) and transmis-
sion electron microscope (TEM). In addition, using advanced techniques in molecular 
biology, we demonstrated that calpain-1 plays an essential role in modulating breast can-
cer cell sensitivity to cisplatin-induced apoptosis. We also showed that the correlation of 
its expression to the proliferating/apoptotic index using immunohistochemical staining 
in TNBC tissue was variable. Exploring new pathways will help in overcoming chemo-
resistance in breast cancer cells.
Keywords: triple-negative breast cancer, platinum-based drugs, cisplatin, calpain-1, 
apoptosis
1. Introduction
Breast cancer is ranked second as one of the leading cause of deaths among women worldwide 
[1]. It is characterized by heterogeneity displaying a wide scope of morphological features, 
different immunohistochemical profiles, and unique histopathological subtypes. According 
to immunohistochemical phenotypes [i.e., presence or absence of estrogen receptor (ER), 
progesterone receptor (PgR), and epidermal growth factor receptor 2 (HER2)], breast cancer 
can be classified into five subtypes. These are luminal A, luminal B, HER2 overexpression, 
basal-like, and normal-like subtypes, each of which has distinct clinical outcomes [2]. Luminal 
A accounts for 50% of invasive breast cancers and are ER/PgR positive or HER2 negative. 
Luminal B category represents 20% of invasive breast cancers. The ER/PgR is positive, while 
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HER2 expression is variable (positive or negative). Luminal B tumors have higher prolifera-
tion and poorer prognosis than luminal A tumors. HER2 overexpression group accounts for 
15% of all invasive breast cancers and the tumor usually tends to be ER/PR negative. The basal 
class is typically ER/PR negative and HER2 negative, hence the name TNBC [3]. It comprises 
about 15% of all invasive breast cancers and have a fairly poor prognosis. Normal-like tumors 
account for 7.8% of all breast cancer cases in a lymph-node negative cohort. It is positive for 
ER and PgR but negative for HER2 [4, 5].
Due to this heterogeneity, the treatment is complicated and the therapeutic strategies should 
be selected carefully. To overcome the disease, it is imperative that each patient be treated 
individually according to the morphological classification with molecular parameters and 
sensitivity to available therapy. Treatment of breast cancer includes surgery, radiation ther-
apy, hormone-modification therapy and chemotherapy (anticancer drugs). Chemotherapy 
treatment has markedly reduced the risk for recurrence and mortality after primary treatment 
of breast cancer and have increased the 5- and 10-year survival rates [6].
One of the major modes of action of chemotherapeutic drugs may be the activation of apopto-
sis (programmed cell death) [7]. Hence, anticancer drugs are associated with the activation of 
proapoptotic genes and the suppression of antiapoptotic genes. The attenuation of proapop-
totic genes and increases in antiapoptotic genes causes resistance to apoptosis [8]. Hence, in 
order to increase the therapeutic effect of chemotherapy, there is a need to assess the molecu-
lar mechanisms of apoptosis induced anticancer drugs. This may lead to new strategies for 
the enhancement of the antitumor effect against target organs.
In this chapter, we hope to summarize three attempted molecular biology studies on breast 
cancer that have contributed to further knowledge in this field. We have compared the effects 
of platinum based-chemotherapeutic drugs such as cisplatin, carboplatin and oxaliplatin on 
the ultrastructure of the three human breast cancer cell lines representing the most diagnosed 
types; MDA-MB-231, MCF-7 and BT-474 [9]. We have particularly demonstrated the role of 
cisplatin in inducing apoptosis in MDA-MB-231 via the endoplasmic reticulum- mediated 
calpain-1 pathway [10]. At the same time, we have assessed the expression of calpain-1 as 
a potential prognostic factor in TNBC tissues [11]. Understanding the pathways by which 
platinum-based drugs induce apoptosis and how these pathways are altered in chemoresis-
tance can provide valuable information necessary to target specific cell death pathways in the 
treatment of clinically resistant breast cancer.
2. Platinum-based drugs and breast cancer cells
Platinum-based drugs (PBDs) are used for adjuvant chemotherapy to reduce mortality from 
breast cancer with reversible side-effects [12]. A key feature of platinum based drugs is that 
once platinum salts enter cells, they can bind to DNA to form Platinum-DNA adducts that 
can cause damage to the DNA. Following DNA damage, cell cycle checkpoints are activated 
to repair either the damaged DNA or induce apoptosis (cell death) [13, 14]. Thus, the ultimate 
goal in the application of platinum-based chemotherapy is to shift the dynamics away from 
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cell growth and survival in favor of cell differentiation and apoptosis. This will in turn reduce 
and eliminate tumor progression and malignancy [15].
Although PBDs are initially effective, their efficacy is limited by the occurrence of resistance, 
which is attributed to alterations in cellular pathways such as DNA repair, drug transport, 
drug metabolism and apoptosis [16]. Several studies have explored the cellular and molec-
ular pathways involved in the mechanism of PBDs resistance to breast cancer [13, 16–18]. 
However, only a few ultrastructural studies on the intracellular organelles of breast cancer 
cells have been performed to determine the effectiveness of these drugs.
2.1. Surface structure of breast cancer cells differ from normal breast cells
We used SEM to compare the surface morphology between three models of breast cancer 
cells, each of which is characterized with a distinct immunohistochemical profile. The MCF-7 
cell line was used to represent the luminal A breast cancer [19], the BT-474 cell line, the lumi-
nal B tumor [20] and the MDA-MB-231 cell line, the basal-like subtype, TNBC [3].
Normal breast cells, MCF-10A, revealed round shape cells characterized by short lamellipodia, 
whereas, the breast cancer cells had a semiflattened surface structure containing microvilli with 
extending lamellipodia. Lamellipodia consist of protrusive filamentous actin and signaling 
proteins, which play a role in cell migration and cell–cell communication. These surface pro-
trusions are important in enhancing movement and adhesion to the surrounding stroma [21]. 
They appeared to be lesser in number and finer in shape for both MCF-7 and BT-474 cells but 
higher in number and thicker for MDA-MB-231 cells. Since MDA-MB-231 cells are advanced 
cancer cells with metastatic characteristics, therefore it is not surprising for these cells to con-
tain higher numbers of lamellipodia on their cell surface. This is indicative of their importance 
of cell shape modifications in their invasiveness process unlike the normal breast cells. These 
distinct features of TNBCs in vivo models might demonstrate their aggressiveness and give 
them a metastatic potential [21–23]. TEM micrographs revealed the absence of nuclei in the 
MDA-MB-231 cells whereas more than one nucleus were detected in MCF-7 and BT-474 cells.
2.2. Effect of PBDs on the cell membrane of breast cancer cells
Treatment with cisplatin, carboplatin and oxaliplatin, using two concentrations of 10 and 
20 μm with the time period of 15 minutes, the initial response of the treated breast cancer cells 
started with the formation of pores on the cell membranes indicating the active process of drug 
influx/efflux. The pores on the surface of the MDA-MB-231 cells were deeper and wider due to 
the high number of lamellipodia, unlike the two cell types; MCF-7 and BT-474. Subsequently 
the lamellipodia retracted causing the cells to shrink and change their shape to semioval and 
to round shape. This was more evident to a higher extent in the MDA-MB-231 cells.
When we treated all the three types of breast cancer cells for 12 hours with the three types of 
PBDs, SEM revealed the early stages of apoptosis presented by convoluted membrane, mem-
brane blebs and apoptotic bodies. The membrane blebbing is caused by deep cytoskeleton 
rearrangement as result of alterations in organelle distribution and cell shape, a pattern of 
apoptosis. Differences on the response of the cells to the three types of PBDs were detected 
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for BT-474 and MCF-7 cells. BT-474 cells sensitivity response was maximal for Carboplatin 
whereas MCF-7 cells sensitivity response was maximal for cisplatin. However, MDA-MB-231 
cells response was similar for all the PBDs. Hence, cell mediated drug response is dependent 
on the cellular characteristic and the drug action.
2.3. Effect of PBDs on the intracellular organelles of breast cancer cells
We then used TEM to gain further insight into the ultrastructural alterations induced by PBDs 
and to study how the drug cytotoxicity differentially caused these alterations. Other distinct 
morphological characteristics of apoptosis consistent with the literature were evident such 
as shrinkage of the cytoplasm, microvilli retraction, fragmentation and condensation of the 
nucleus and swelling of both the mitochondria and endoplasmic reticulum [24, 25]. Splitting 
of apoptotic cells characterizes the final stage of apoptosis [24]. In addition to apoptosis, TEM 
micrographs also revealed the necrotic type of death. Changes identified on plasma mem-
brane shows incoherence, causing cell swelling and organelles disruption. Occasionally, 
apoptotic cells, in vitro, undergo a late process of secondary necrosis. Necrosis was considered 
to be a physical process of cell death that was not regulated. However, emerging evidence 
suggests that it is as another form of apoptosis and an independent genetically encoded cell 
death pathway [25, 26]. Overall, treated cells with the three types of PBDs exhibited similar 
ultrastructural changes exhibiting distinct features such as the increased number of vacuoles 
portraying as a defense mechanism for cell survival and this is consistent with other studies 
in other types of cancers [27–29]. PBD deposits were mainly attracted to the fat droplets of the 
cells suggesting an active role of cellular lipids in the potentiation of PBDs to induce apoptosis.
Few but prominent differences between the three types of breast cancer cells were detected 
when treated with PBDs. These included the following;
1. Carboplatin did not cause any swelling and disarrangement of the mitochondria on the 
BT-474 and the MDA-MB-231 cells as opposed to the MCF-7 cells.
2. Carboplatin-treated cells exhibited more lamellar bodies compared to cisplatin or oxaliplatin 
treated cells. Lamellar bodies are specialized lipid storage or secretory organelles, which have 
a core composed of multilamellar structure and can be surrounded by a membrane [30]. It is 
possible that PBDs induce lipidosis in cancer cells and cause accumulation of lamellar bodies.
3. Carboplatin, cisplatin and oxaliplatin caused apoptosis in all the three types of breast can-
cer cell lines, however, it is possible that apoptosis independent of DNA damage could 
have contributed to the way some of the enucleated cells of the MDA-MB-231 cells die. 
This will be discussed further in Section 3.
3. Cisplatin-induced calpain-1 activation by endoplasmic reticulum 
in TNBC cells
Cisplatin has been shown to induce apoptosis in enucleated cells [31, 32]. It does this by ini-
tially acting on the endoplasmic reticulum causing an increase in cytosolic calcium (Ca2+), 
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leading to the activation of calpain-1 [33]. Calpains belong to a family of Ca2+-dependent 
proteases which play many roles in basic cellular processes including cell proliferation and 
apoptosis, through activation of the caspase pathways. Calpain-1 and calpain-2, encoded by 
CAPN1 and CAPN2, respectively, are the most abundant isoforms within their family [31]. 
Although we, and others, have shown that cisplatin-induced apoptosis occurs by way of the 
calpain-1 dependent pathway, [34–36]; however, information in TNBC cells is limited. This 
prompted us to investigate the role of the calpain-1 pathway by way of the endoplasmic retic-
ulum in the apoptotic death of TNBC cells induced by cisplatin.
3.1. Cisplatin caused calcium release in TNBC cells
Using Von Koss staining, we were able to represent the variation of Ca2+ deposits between 
the cisplatin-treated and untreated TNBC cells. Ca2+ deposits in the cytoplasm increased with 
increasing cisplatin concentration (0, 20 and 40 μm) in the cisplatin-treated cells with no sig-
nificant deposits observed in the untreated cells.
3.2. Cisplatin caused structural changes in the endoplasmic reticulum of TNBC cells
Several studies have concentrated on the investigation of non-nuclear pathways in the 
apoptosis of cancer cells induced by cisplatin [31, 32, 34]. Such studies contribute to the 
understanding of the causes of sensitivity and resistance to cisplatin [31, 37]. The endoplas-
mic reticulum is involved in the regulation of cellular responses to stress and alterations 
in Ca2+ homeostasis [38]. Alterations in Ca2+ homeostasis and accumulation of misfolded 
proteins in the endoplasmic reticulum caused endoplasmic reticulum stress resulting in 
apoptosis [39]. Using TEM, we detected the intracellular deposits of cisplatin and its struc-
tural changes on the endoplasmic reticulum in TNBC cells. TEM micrographs revealed 
that cisplatin induced clear structural changes in both the endoplasmic reticulum and the 
mitochondria. This phenomenon represented swelling of the lumen and disarrangement of 
their internal folding as compared to the control cells without treatment which appeared as 
well-defined structures. Hence, these findings were consistent with a study conducted by 
Mandic et al. who demonstrated that the endoplasmic reticulum is the non-nuclear target 
of cisplatin [31].
3.3. Location of calpain-1 in TNBC cells
Studies have reported that calpain-1 is mainly located in the cytoplasm of breast cancer cells 
[40, 41]. We also used immunohistochemical staining to confirm this finding. The staining 
intensity of calpain-1 in the cytoplasm increased with increasing concentrations (0, 20 and 
40 μm) of cisplatin.
3.4. Cisplatin activated calpain-1 and induced apoptosis through the endoplasmic 
reticulum-mediated pathway
The results of some experiments attempted to investigate the role of calpain-1 in the apoptotic 
death of TNBC cells induced by cisplatin by way of the endoplasmic reticulum are summa-
rized in Table 1.
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We have shown in this study the effect of cisplatin on calpain-1 protein and its activation in 
TNBC cells. This has also been reported by others in other types of cancer cells [34, 35]. The 
finding that the increase in both calcium deposits and upregulation of endoplasmic  reticulum 
Experiments Results
Control (μm/nM) Treatment after 24 hours P value of 
apoptosis
Cisplatin to induce 
endoplasmic 
reticulum stress 
(calcium release) and 
activate calpain-1 was 
assessed as activation 
of endoplasmic 
reticulum downstream 
effectors; α-fodrin and 
caspase-12.
Calpain-1, α-fodrin 
and caspase-12 protein 
content (total and 
cleaved) was measured 
by Western blotting.
Cisplatin (0 μm) Cisplatin (20 μm) Cisplatin activated 
calpain-1 as 
reflected in cleavage 
of α-fodrin and 
caspase-12 and 
induced apoptosis 
in TNBC cells. 
Although cisplatin 
had no effect on 
calpain-1 content, it 
significantly caused 
cleavage of α-fodrin 
and caspase-12 and 
induced apoptosis 
in a dose-dependent 
manner [10].
P < 0.001 vs. 
control
Cisplatin (0 μm) Cisplatin (40 μm) P < 0.001 vs. 
control
Cisplatin to activate 
calpain-1 by way 
of endoplasmic 
reticulum using 
CPA treatment was 





and caspase-12, were 
measured using 
immunoblotting.
Cisplatin (0 μm) + CPA 
(50 μm)








compared with the 
controlled group 
[10].
P < 0.001 vs. 
CPA Control
Cisplatin to activate 
calpain-1 by way 
of endoplasmic 
reticulum using 
siRNA treatment was 
assessed as activation 
of α-fodrin. The effect 
of calpain-1 siRNA 
on its content and 
activation (indicated 
by α-fodrin cleavage) 
was measured using 
immunoblotting
Cisplatin 
(0 μm) + calpain-1 
siRNA (150 nM)
Cisplatin 







in TNBC cells by 
downregulating 
calpain-1 in TNBC 
cells [10].
P < 0.01 vs. 
Calpain-1 
siRNA Control
Apoptosis was measured by Hoechst staining using fluorescent microscopy.
Table 1. Summary of results of experiments attempted to investigate the role of calpain-1 in the apoptotic death of TNBC 
cells induced by cisplatin by way of the endoplasmic reticulum.
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stress indicator proteins such as GRP78 and calmodulin suggest the involvement of endo-
plasmic reticulum stress-dependent Ca2+ release in the cellular mechanism of action of cis-
platin. The ability of cisplatin-induced apoptosis by way of endoplasmic reticulum stress has 
been shown to involve calpain-mediated activation of caspase-12 [42]. Caspase-12 is local-
ized to the endoplasmic reticulum and may be activated by the disturbance of intracellu-
lar calcium homeostasis [43]. Cyclopiazonic acid (CPA) is a selective Ca2+ ATPase inhibitor, 
which depletes the endoplasmic reticulum (ER) of Ca2+ and therefore, activates Ca2+ − depen-
dent proteases such calpain. For that reason, the activity of calpain-1 was enhanced by CPA 
through the endoplasmic reticulum-mediated pathway which further increased the TNBC 
cells response to cisplatin-induced apoptosis. In contrast, the sensitivity was attenuated by 
calpain-1 inhibition using the exogenous inhibitor, calpain-1 siRNA. These findings support 
the role of calpain-1 responsible for the pro-apoptotic effects of cisplatin in TNBC cells by 
way of endoplasmic reticulum. Hence, targeting calpain-1 activity with specific inhibitors 
could be a novel approach in limiting development of primary tumors and formation of 
metastases.
4. Calpain-1 as a potential prognostic factor in TNBC
TNBC has been reported to have a clinical and pathological aggressive pattern due to its 
heterogeneous characteristic [44]. The ineffectiveness of hormonal and targeted therapies 
and poor prognosis for this subtype requires developing alternative therapeutic strategies 
such as biomarkers. The expression of a number of proteins has been shown to be associated 
with clinical outcome in TNBC patients [40, 45, 46]. Hence, there is a need to identify addi-
tional biomarkers to allow personalized treatment for patients with TNBC. For this reason, 
we explored the role of calpain-1 as a potential prognostic factor for TNBC therapy. We also 
evaluated the proliferation and apoptotic index for their potential use as possible prognostic 
factors since the biological behavior of tumor growth is a result of a balance between the 
proliferative activity and the number of cells dying by apoptosis [47]. Thus, they are consid-
ered as dominant histopathologic features in tumors. Several studies have also shown that 
calpain-1 expression significantly associated with tumor grade [40], proliferation [48, 49] and 
apoptosis [50]. Therefore, we also assessed the association between calpain-1 expression, cell 
proliferation and apoptosis in TNBC tissues.
4.1. Patient characteristics
We tested calpain-1 protein expression and the proliferative/apoptotic index on paraffin-
embedded tissues from a cohort of 55 patients with TNBC. The main histological type was 
infiltrative ductal carcinoma in 96.4% (53 of 55), infiltrative lobular carcinoma in 1.8% (1 of 
55) and micropapillary carcinoma 1.8% (1 of 55). Patients were females with a median age 
of 47 years (19–74). A total of 34 cases (61.8%) were premenopausal with no family history 
of breast cancer. Based on the disease indexing system, half (50.9%) of the patients were 
defined as stage III or IV at the time of diagnosis. Almost half of the patients (𝑛 = 26, 47.3%) 
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received neoadjuvant treatment and 5 (19.2%) achieved complete pathological response. 
Anthracyclines and taxanes were the most commonly used chemotherapeutic agents as front-
line treatment. Breast cancer related overall survival (OS) was defined as the time interval (in 
months) from the date of diagnosis until death from breast cancer. Similarly, recurrence-free 
survival (RFS) was defined as the time interval (in months) between the start of primary treat-
ment and date of cancer relapse.
4.2. Calpain-1 expression in TNBC tissues
Immunostained tissues with calpain-1 were significantly expressed and demonstrated cyto-
plasmic and membranous staining with some granularity and heterogeneity between adjacent 
tumor cells varying from weak to intense staining in which low staining was detected in 32.7% 
(18 of 55), intermediate staining in 38.2% (21 of 55) and high staining in 29.6% (16 of 55) of the 
cases analyzed. The cut off value was determined by screening the stained tissue under light 
microscope where the staining intensity of calpain-1 in tumor cells was assessed as none (0), 
weak (1), medium (2), and strong (3) using an immunohistochemical H-score. The H-scores 
were calculated by multiplying the percentage area by the intensity grade (H-score range 0–300).
4.3. Correlation between calpain-1 expression and clinicopathological variables and 
outcome of TNBC patients
In order to investigate the possibility of using calpain-1 protein as a prognostic biomarker in 
TNBC, its expression was assessed for association with a number of clinicopathological vari-
ables. We determined that calpain-1 expression displayed a significant positive association 
to the lymph node status (P = 0.02) but not with other clinicopathological variables. Kaplan–
Meier survival curves were plotted with significance determined using the log-rank test in 
order to determine the relationship between calpain-1 protein expression in the recurrence-
free survival (RFS) and in the overall survival (OS) patients. The expression of calpain-1 in 
the triple-negative tissues was not significantly associated with breast cancer RFS (𝑃 = 0.71) or 
OS (𝑃 = 0.88) in which the median RFS was 18 months (3–77 months) and OS was 41 months 
(0–105 months) in the total patient cohort.
TNM classifies lymph node status as a tumor-related prognostic factor, therefore, our results 
suggest that calpain-1 might be used as a prognostic factor in TNBC. Calpain-1 was also found 
to be associated with lymph node status in other types of cancer, such as renal cell carcinoma 
[51]. The observation of the lack of association of calpain-1 with other clinicopathological 
variables is consistent with a study conducted by Storr et al. in which they demonstrated a 
correlation between calpain-1 expression and tumor grade but not with other clinicopatho-
logical variables [40].
The variations among the presence or absence of association with lymph node status or tumor 
grade which are essential in determining its prognosis can be explained by several theories; 
(i) the majority of patient samples were of intermediate grade tumor and therefore calpain-1 
activity may have started at later stages as suggested by its correlation with the lymph node 
status, (ii) the lack of wide range of sample collection in regards to tumor grades may have 
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created a diversion in the statistical analysis, (iii) the insufficiency of samples might have con-
tributed to lack of significant correlations, (iv) the possibility of genetic differences between 
the populations in the current study and the ones already published may be the cause of 
differences on the expression of calpain-1 in breast cancer cells [40] and finally (v) the pres-
ence or absence of the hormonal receptors such as ER, PR, and HER2 that determine breast 
cancer behavior and thus treatment can influence the outcome. Storr et al. (2011) reported that 
there was no association between the expression of calpain-1 in HER2-positive breast cancer 
patients treated with trastuzumab following adjuvant chemotherapy with any of the clinico-
pathological variables [52]. Hence, their observation is consistent with our data but may differ 
in terms of the positivity of HER2.
4.4. Association between calpain-1 expression, cell proliferation and apoptosis in 
TNBC tissues
Calpains have been reported to be involved in the proliferation of breast cancer cells [48, 49]. 
However, the role of the calpain family in proliferation of TNBC cells has not been reported yet. 
Ki-67, a nuclear antigen is a protein encoded by Ki-67 on 10q25 and considered to be a prolifera-
tion marker for predicting tumor development [53]. It is expressed during all active phases of 
the cell cycle except the resting phase, thus being present only in dividing cells. Ki-67 is detected 
by monoclonal antibody MIB-1 which can be a useful marker of proliferation and of prognostic 
value [53]. The quantitative assessment of Ki-67 staining on paraffin embedded tumor sections 
has been reported as an accurate estimate of the proliferation index of individual tumors [53].
Therefore, proliferative fractions of paraffin embedded breast cancer tissues were determined 
by immunohistochemical staining for Ki-67 antibody. The cellular proliferative activity was esti-
mated as the percentage of tumor cells stained per field ×40. Statistical analysis showed no sig-
nificant correlation between calpain-1 expression and proliferation (𝑃 = 0.29). Possible theories 
of the presence and absence of the hormonal receptors, differences in the genetic makeup, and 
other members of calpains involvement may also influence the correlation with proliferation.
Cell proliferation along with cell death are both phenomena responsible for control of cell 
number in normal tissues and tumors. Since chemotherapy induces programmed cell death 
by apoptosis, hence, the apoptotic tumor cells can be morphologically identified using the con-
ventional hematoxylin and eosin (H&E) method and cells are counted using light microscopy. 
Therefore, there has been interest in the application of the apoptotic index in malignant growths 
as a putative prognostic marker. The percentage of apoptotic cells in tumor sections may also be 
measured by a molecular-based approach, labeling of fragmented DNA breaks and calculating 
the apoptotic index (AI) using the terminal transferase-uridyl nick-end labeling (TUNEL) assay.
Therefore, in order to determine whether the frequency of apoptosis was related to tumori-
genesis, two approaches; the conventional H&E staining method and the apoptotic TUNEL 
assay were both used to detect apoptotic cells and to prove that the two methods compara-
tively correlate with each other. H&E detects apoptosis in its degradation phase and can be 
subjective whereas the TUNEL assay detects apoptosis in its early phase and is more objective. 
Apoptotic cells were counted per 100 invasive tumor cells using ×40 objective. Apoptotic counts 
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using either method, were significantly correlated (𝑃 < 0.001, 𝑟 = 0.547). Although both assays 
tested apoptosis from different aspects, but the results were the same, indicating the reliability 
of both assays. These findings were also consistent with a previous study by Watanabe et al. 
[54]. In addition, the relationship between apoptosis and proliferation was investigated in TNBC 
tissues. For all of the patients, high apoptotic counts significantly correlated with increased cell 
proliferation (𝑃 = 0.045). The positive correlation between proliferative and apoptotic indices 
seen in this study is also consistent with other types of cancers such as colorectal cancers [54].
In experimental models the calpain system has been shown to influence apoptosis in breast 
cancer [48, 55, 56]. The relationship between calpain-1 expression and apoptosis using the 
two methods, H&E-based apoptotic counts and apoptotic counts derived from the apoptotic 
TUNEL assay was investigated in the TNBC tissues. Interestingly, the data revealed that 
there were no significant association between the apoptotic indices when compared to cal-
pain-1 expression (𝑃 = 0.710 and 0.100), respectively. Such results suggest that the TNBC cells 
undergo apoptosis via other members of the calpain family such as calpain-2.
Taken together, these data have clearly demonstrated the absence of correlation between 
calpain-1 expression and the proliferating/apoptotic index or clinicopathological variables 
except with the lymph node status of TNBC patients. Hence, calpain-1 could be a useful prog-
nostic marker in TNBC. More studies should be conducted in the future to evaluate the prog-
nostic value of calpain-1 in TNBC.
5. Conclusion
Breast cancer is the most leading cause of cancer death in females worldwide. Although its 
name is based on a single tissue of origin, this cancer is heterogeneous making it a complex 
disease. Compared to other subtypes of breast cancer, TNBC is more biologically aggressive 
and has higher recurrence rate, higher frequency of metastasis and worse survival. Challenges 
into identifying targets and treatments have led to advances in laboratory technology and 
research resulting into the expansion of our knowledge of tumor biology. Though no spe-
cific therapies currently exist for TNBC except for cytotoxic chemotherapy, there is ongo-
ing research to identify potential targets for therapy. Therefore, the understanding of breast 
cancer subtypes and targeted drug therapies is a key to address resistance to current targeted 
drugs in order to pave the way for providing personalized breast cancer care.
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